Related-party Transactions	3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]
Related-party Transactions	Related-party TransactionsIn September 2021, the Company entered into a sublease with Sonoma, with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr. Klausner, the Chair of the Company’s board of directors, also serves as a member of the board of directors of Sonoma. As a part of the sublease, a $4.6 million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the sublease. As of both March 31, 2023 and December 31, 2022, there were accrued liabilities and other current liabilities of $0.5 million and as of March 31, 2023 and December 31, 2022, there were other non-current liabilities of $3.4 million and $3.5 million, respectively, in connection with the sublease with Sonoma. Income of $0.7 million was recognized in other operating income, net for both the three months ended March 31, 2023 and 2022, of which $0.5 million was attributed to sublease income for both the three months ended March 31, 2023 and 2022. See Note 7, Leases, for more detail on the Sonoma sublease.The Company was party to the GSK Agreement with GSK, who is a holder of more than 10% of the Company’s outstanding common stock. See Note 3, License, Collaboration and Success Payment Agreements. GSK terminated the GSK Agreement effective December 24, 2022. The Company had no current or non-current deferred revenue in connection with the GSK Agreement as of both March 31, 2023 and December 31, 2022. Revenue recognized in connection with the GSK agreement was zero and $0.6 million for the three months ended March 31, 2023 and 2022, respectively.

Related-party Transactions

3 Months Ended

Mar. 31, 2023

Related-party TransactionsIn September 2021, the Company entered into a sublease with Sonoma, with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr. Klausner, the Chair of the Company’s board of directors, also serves as a member of the board of directors of Sonoma. As a part of the sublease, a $4.6 million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the sublease. As of both March 31, 2023 and December 31, 2022, there were accrued liabilities and other current liabilities of $0.5 million and as of March 31, 2023 and December 31, 2022, there were other non-current liabilities of $3.4 million and $3.5 million, respectively, in connection with the sublease with Sonoma. Income of $0.7 million was recognized in other operating income, net for both the three months ended March 31, 2023 and 2022, of which $0.5 million was attributed to sublease income for both the three months ended March 31, 2023 and 2022. See Note 7, Leases, for more detail on the Sonoma sublease.The Company was party to the GSK Agreement with GSK, who is a holder of more than 10% of the Company’s outstanding common stock. See Note 3, License, Collaboration and Success Payment Agreements. GSK terminated the GSK Agreement effective December 24, 2022. The Company had no current or non-current deferred revenue in connection with the GSK Agreement as of both March 31, 2023 and December 31, 2022. Revenue recognized in connection with the GSK agreement was zero and $0.6 million for the three months ended March 31, 2023 and 2022, respectively.